Vandetanib
Hereditary Leiomyomatosis And Renal Cell Cancer
Explore 8 assets in Hereditary Leiomyomatosis And Renal Cell Cancer →Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02495103CT.gov Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Hereditary Leiomyomatosis And Renal Cell Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vandetanib (this asset) | National Cancer Institute (NCI) | P1/2 | CCC · 48 |
| Pamiparib | Jonsson Comprehensive Cancer Center | P2 | CCC |
| Dentalfluoro | National Cancer Institute (NCI) | P2 | CCC |
| Atezolizumab | National Cancer Institute (NCI) | P2 | CCC |
| Metformin | National Cancer Institute (NCI) | P1/2 | CCC |
| Lactate | University of Texas Southwestern Medical Center | N/A | D |
| Glucose, Anhydrous | University of Texas Southwestern Medical Center | N/A | D |
| Glutamine | University of Texas Southwestern Medical Center | N/A | D |
| 13C-Fructose | University of Texas Southwestern Medical Center | N/A | D |
+1 more in the Hereditary Leiomyomatosis And Renal Cell Cancer cohort
Other indications for Vandetanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | B · 63 |
| Metastatic Neoplasm | — | P2 | B · 63 |
| Non-Small Cell Lung Carcinoma | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vandetanib in Hereditary Leiomyomatosis And Renal Cell Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vandetanib-hereditary-leiomyomatosis-and-renal-cell-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →